InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-27.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Martin Samuel Bates, Chief Financial Officer. Officer active across 1 company, notably Celldex Therapeutics, Inc.. Aggregated, 10 filings have been logged. Activity tracked since 10 August 2021. The latest transaction was disclosed on 14 June 2024 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations10 total
3,201 shares@ US$9.01654.7% of flowCommon StockSEC:0001415889-24-017363:0
25,000 shares@ US$10.3841.6% of flowCommon StockSEC:0001415889-24-015147:0
10,750 shares@ US$2.784.7% of flowCommon StockSEC:0001415889-24-000592:0
2,453 shares@ US$9.01653.7% of flowCommon StockSEC:0001415889-22-008608:0
3,250 shares@ US$9.01654.5% of flowCommon StockSEC:0001179110-21-011251
3,250 shares@ US$9.01650.0011% mcap9.9% of flowCommon StockSEC:0001179110-21-011251:0
3,250 shares@ US$9.01650.0010% mcap9.8% of flowCommon StockSEC:0001179110-21-010208:0
3,250 shares@ US$9.01654.4% of flowCommon StockSEC:0001179110-21-010208
10,302 shares@ US$9.016513.7% of flowCommon StockSEC:0001179110-21-008140
10,302 shares@ US$9.01650.0032% mcap30.3% of flowCommon StockSEC:0001179110-21-008140:0
10 of 10 declarations
About Martin Samuel Bates
Samuel Bates Martin is the Chief Financial Officer and Senior Vice President of Celldex Therapeutics, Inc. He is responsible for the financial management of the company, overseeing accounting operations and financial reporting. Samuel Bates Martin plays a key role in developing financial strategies to support the growth of Celldex.
